RON 不是可切除胰腺癌的预后标志物。
RON is not a prognostic marker for resectable pancreatic cancer.
机构信息
Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, Sydney, NSW 2010, Australia.
出版信息
BMC Cancer. 2012 Sep 7;12:395. doi: 10.1186/1471-2407-12-395.
BACKGROUND
The receptor tyrosine kinase RON exhibits increased expression during pancreatic cancer progression and promotes migration, invasion and gemcitabine resistance of pancreatic cancer cells in experimental models. However, the prognostic significance of RON expression in pancreatic cancer is unknown.
METHODS
RON expression was characterized in several large cohorts, including a prospective study, totaling 492 pancreatic cancer patients and relationships with patient outcome and clinico-pathologic variables were assessed.
RESULTS
RON expression was associated with outcome in a training set, but this was not recapitulated in the validation set, nor was there any association with therapeutic responsiveness in the validation set or the prospective study.
CONCLUSIONS
Although RON is implicated in pancreatic cancer progression in experimental models, and may constitute a therapeutic target, RON expression is not associated with prognosis or therapeutic responsiveness in resected pancreatic cancer.
背景
受体酪氨酸激酶 RON 在胰腺癌进展过程中表达增加，并促进实验模型中胰腺癌细胞的迁移、侵袭和吉西他滨耐药性。然而，RON 表达在胰腺癌中的预后意义尚不清楚。
方法
在包括一项前瞻性研究在内的几个大型队列中对 RON 表达进行了特征描述，共包括 492 名胰腺癌患者，并评估了与患者结局和临床病理变量的关系。
结果
在训练集中，RON 表达与结局相关，但在验证集中没有重现，在验证集中或前瞻性研究中也与治疗反应性没有任何关联。
结论
尽管 RON 在实验模型中参与了胰腺癌的进展，并且可能构成治疗靶点，但 RON 表达与切除的胰腺癌的预后或治疗反应性无关。
Zotero 插件